Geert Verleden
Pneumologist, formerly head of pneumology at UZ Leuven and professor at KU Leuven, now part-time at UZA, with lung transplantation as his main discipline.
As of . Primary source: UZA profile (Dutch).
Summary
According to his UZA profile (in Dutch), Geert Verleden was a staff member at UZ Leuven from August 1990 until his emeritus status in October 2023, with lung transplantation as his main discipline, head of the pneumology department from 2014 to 2023 and full professor at KU Leuven from 2015. Since October 2024 he has been a part-time consultant in lung transplantation at UZA. The profile does not describe CLAD research in detail; his CLAD-related publications are recorded on the linked paper records.
Ranking method and caveats
Methodology for the researcher ranking
- Query: OpenAlex works of type article or review whose title or abstract contains "chronic lung allograft dysfunction" or "restrictive allograft syndrome", or "bronchiolitis obliterans" together with lung transplant terms. Retracted works and meeting-abstract supplements are removed.
- Window and date: works published 2016-10-11 to 2026-10-10; counts retrieved 2026-10-10 (2,461 works, 8,698 author profiles after merging).
- Counting: the rank is by total citations of the author's papers (whole counting). Fractional counts, first or last author papers and counts without the two 2019 ISHLT consensus papers are shown on each record.
- Identity: authors are identified by OpenAlex author identifier and ORCID. Duplicate profiles were merged by identical ORCID, or by compatible name plus shared institution. Only the top 30 entries were checked by hand.
- Rising researchers: a separate numbered list ordered by citations in the 5 years from 2021-10-11, for authors whose first paper in the corpus is dated 2019 or later and who have at least 5 papers in that window. It is a proxy, not a measure of career stage.
- Caveats: the corpus includes papers only partly about CLAD; consensus papers inflate some totals; recent papers are under-cited; author identifiers can be wrong; citations measure attention, not quality or clinical skill.
Details
- role
- Pneumologist; emeritus professor (KU Leuven); part-time consultant (UZA)
- affiliation
- KU Leuven and UZ Leuven (to 2023); UZA (from 2024)
- citation rank 10y
- 2 of 8,698 author profiles (top 100 listed)
- papers 10y
- 93
- fractional papers 10y
- 10.42
- citations 10y
- 3141
- fractional citations 10y
- 337.8
- lead author papers 10y
- 18
- citations excluding two ishlt2019consensus papers
- 1888
- rank excluding two ishlt2019consensus papers
- 2
- ranking retrieved
- 2026-10-10
- orcid
- 0000-0003-3048-2429
- openalex author id
- A5069256258
- merged open alex profiles
- 3
- affiliation basis
- unverified; OpenAlex lists "University of Antwerp" on the most recent corpus paper (2026). Not confirmed as current.
Sources and links
- UZA profile (Dutch) (primary)
- OpenAlex author profile (ranking source)
- ORCID record
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT (The Journal of Heart and Lung Transplantation, 2019); 952 citations; DOI 10.1016/j.healun.2019.03.009
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome―A consensus report from the Pulmonary Council of the ISHLT (The Journal of Heart and Lung Transplantation, 2019); 301 citations; DOI 10.1016/j.healun.2019.03.008
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction phenotypes and treatment (Journal of Thoracic Disease, 2017); 125 citations; DOI 10.21037/jtd.2017.07.81
- Most-cited CLAD paper in corpus: Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions (ERJ Open Research, 2022); 62 citations; DOI 10.1183/23120541.00185-2022
- Most-cited CLAD paper in corpus: Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial (PLOS ONE, 2018); 59 citations; DOI 10.1371/journal.pone.0193564
Related
Links from this record
- member of: KU Leuven BREATHE (Laboratory of Respiratory Diseases and Thoracic Surgery)
- author: A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation
- author: Beyond Bronchiolitis Obliterans: In-Depth Histopathologic Characterization of Bronchiolitis Obliterans Syndrome after Lung Transplantation
- author: Chronic lung allograft dysfunction and restrictive allograft syndrome: are phenotypes robust and helpful?
- author: Novel biomarkers of chronic lung allograft dysfunction: is there anything reliable?
- author: The ABC of transplant: ALAD, BLAD, and CLAD: definition and significance
- author: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment: A consensus report from the Pulmonary Council of the ISHLT
- author: Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome: A consensus report from the Pulmonary Council of the ISHLT
- author: Chronic lung allograft dysfunction phenotypes and treatment
Linked from (derived)
- coauthor: A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation
- coauthor: Beyond Bronchiolitis Obliterans: In-Depth Histopathologic Characterization of Bronchiolitis Obliterans Syndrome after Lung Transplantation
- coauthor: Chronic lung allograft dysfunction and restrictive allograft syndrome: are phenotypes robust and helpful?
- coauthor: Novel biomarkers of chronic lung allograft dysfunction: is there anything reliable?
Known gaps in this record
- current funding
- ORCID identifier
- English-language institutional profile
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.